Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.

被引：4

作者：

Shimizu, Toshio

Nakajima, Takako Eguchi

Lu, Ni

Xue, Shilin

Xu, Wenlian

Fu, Meng

Cao, Walt

Lu, Haolan

Liu, David

Dong, RuiPing

Wang, Xiaoxiao

Wang, Pilin

Zhu, Danming

Xu, Ting

Gong, John

机构：

[1] NCCH, Tokyo, Japan

[2] St Marianna Univ, Sch Med, Dept Clin Oncol, Kawasaki, Kanagawa, Japan

[3] 3D Medicines Co Ltd, Sichuan, Sichuan, Peoples R China

[4] 3D Medicines Co Ltd, Beijing, Peoples R China

[5] Alphamab Co Ltd, Suzhou, Peoples R China

来源：

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.2609

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2609

引用

页数：1